A placebo-controlled, double-blinded, randomized clinical trial of anti-TNF [tumour necrosis factor] chimeric monoclonal antibody (cA2) [infliximab] in patients with active rheumatoid arthritis despite methotrexate treatment
Phase of Trial: Phase III
Latest Information Update: 01 Oct 2016
At a glance
- Drugs Infliximab (Primary)
- Indications Rheumatoid arthritis
- Focus Therapeutic Use
- Acronyms ATTRACT
- Sponsors Centocor
- 01 Oct 2016 Results of post-hoc analyses on clinical remission rates using data from infliximab (ASPIRE,ATTRACT) and golimumab (GO-FORWARD) trials, published in the Arthritis and Rheumatology.
- 07 Dec 2006 New trial record.